1st Quarter - Report — NATIONAL ORGANIZATION FOR RARE DISORDER… for NATIONAL ORGANIZATION FOR RARE DISORDER… (2017)

Firm

NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)

Client

NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD)

Income

—

Expenses

—

No amount is shown when the filer reports less than $5,000 for the period, which the form does not ask them to state.

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

American Health Care Act; H.R.1628 Preserving Employee Wellness Act, H.R.1313 Medical Nutrition Equity Act Prescription Drug User Fee Act Reauthorization Medical Device User Fee Act Reauthorization Orphan Drug Tax Credit Right to Try Act; H.R.878, S.204 Pre-existing Conditions Protection Act of 2017; H.R.1121 OPEN Act; H.R.1223 FDA Funding NIH Funding RACE for Children Act; H.R.1231 Zika Appropriations Newborn Screening Appropriations

Lobbyist	Covered position, as disclosed
PAUL MELMEYER	—
MARTHA L RINKER	Vice President of Public Policy

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); White House Office; Social Security Administration (SSA); SENATE; Natl Institutes of Health (NIH); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 878 (115th), H.R. 1313 (115th), H.R. 1628 (115th), S. 204 (115th), H.R. 1231 (115th), H.R. 1223 (115th), H.R. 1121 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.